MTI-HMC Peshawar, Peshawar, Khyber Pukhtunkhwa, 25000, Pakistan - 01 Jun `26Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.

Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.

Official title: Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.

Status: Opening soon

Description:

This study aims to compare the efficacy and safety of PUVA versus Tofacitinib in the treatment of generalized vitiligo. Given the high prevalence of vitiligo in Pakistan and the significant psychosocial impact on patients, particularly in Peshawar, this study will provide valuable insights into optimal treatment strategies.

Phase: Early Phase 1.

What is being studied: drugs — Group A recieving PUVA therapy, Group B receiving Tablet Tofacitinib.

Who can take part: ages 18 Years to 60 Years, 64 participants planned.

Enrollment status: Opening soon. The study started 01 June 2026 and is expected to finish 31 December 2026.

Contact: Sana Zaman, FCPS Part II.

Source: ClinicalTrials.gov, NCT07055529 (https://clinicaltrials.gov/study/NCT07055529).

Start date: June 01, 2026

Completion date: December 31, 2026

Organizer: Hayat Abad Medical Complex, Peshawar

Contact: Sana Zaman, FCPS Part II

Tel.: 92 317 6030615

Email: zamansana16@gmail.com

Link: https://clinicaltrials.gov/study/NCT07055529

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo. . By submitting you agree to our Privacy Policy.

FAQOther Questions